156 related articles for article (PubMed ID: 38701273)
21. High EIF4E2 expression is an independent prognostic risk factor for poor overall survival and recurrence-free survival in uveal melanoma.
Yang B; Gu A; Wu Y
Exp Eye Res; 2021 May; 206():108558. PubMed ID: 33785306
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of deregulated microRNAs in uveal melanomas.
Falzone L; Romano GL; Salemi R; Bucolo C; Tomasello B; Lupo G; Anfuso CD; Spandidos DA; Libra M; Candido S
Mol Med Rep; 2019 Apr; 19(4):2599-2610. PubMed ID: 30816460
[TBL] [Abstract][Full Text] [Related]
23. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
24. Integrated analyses identify potential prognostic markers for uveal melanoma.
Ni Y; Zhang Z; Chen G; Long W; Tong L; Zeng J
Exp Eye Res; 2019 Oct; 187():107780. PubMed ID: 31469983
[TBL] [Abstract][Full Text] [Related]
25. Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.
Gao G; Yu Z; Zhao X; Fu X; Liu S; Liang S; Deng A
Sci Rep; 2021 Nov; 11(1):22244. PubMed ID: 34782661
[TBL] [Abstract][Full Text] [Related]
26. Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma.
Zhang F; Deng Y; Wang D; Wang S
Sci Rep; 2022 Jan; 12(1):1640. PubMed ID: 35102195
[TBL] [Abstract][Full Text] [Related]
27. A novel lncRNA-miRNA-mRNA competitive endogenous RNA network for uveal melanoma prognosis constructed by weighted gene co-expression network analysis.
Yu H; Cheng Y; Li W; Li Z; Wu P; Qiu S; Zeng B; Huang B
Life Sci; 2020 Nov; 260():118409. PubMed ID: 32926921
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.
Hu Y; Cai J; Ye M; Mou Q; Zhao B; Sun Q; Lou X; Zhang H; Zhao Y
Front Immunol; 2022; 13():1037128. PubMed ID: 36466923
[TBL] [Abstract][Full Text] [Related]
29. Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma.
Li Y; Xiong C; Wu LL; Zhang BY; Wu S; Chen YF; Xu QH; Liao HF
Pathol Oncol Res; 2023; 29():1610980. PubMed ID: 37362244
[No Abstract] [Full Text] [Related]
30. Development and Validation of a Novel Metabolic Signature-Based Prognostic Model for Uveal Melanoma.
Shi K; Li X; Zhang J; Sun X
Transl Vis Sci Technol; 2022 May; 11(5):9. PubMed ID: 35536719
[TBL] [Abstract][Full Text] [Related]
31. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
32. Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma.
Xin X; Zhang Y; Ling F; Wang L; Sheng X; Qin L; Zhao X
Exp Eye Res; 2019 Mar; 180():242-249. PubMed ID: 30615885
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Liu QH; Ma LS
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6230-6238. PubMed ID: 30338785
[TBL] [Abstract][Full Text] [Related]
34. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
35. OSuvm: An interactive online consensus survival tool for uveal melanoma prognosis analysis.
Wang F; Wang Q; Li N; Ge L; Yang M; An Y; Zhang G; Dong H; Ji S; Zhu W; Guo X
Mol Carcinog; 2020 Jan; 59(1):56-61. PubMed ID: 31646691
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA expression analysis and Multiplex ligation-dependent probe amplification in metastatic and non-metastatic uveal melanoma.
Larsen AC; Holst L; Kaczkowski B; Andersen MT; Manfé V; Siersma VD; Kolko M; Kiilgaard JF; Winther O; Prause JU; Gniadecki R; Heegaard S
Acta Ophthalmol; 2014 Sep; 92(6):541-9. PubMed ID: 24373459
[TBL] [Abstract][Full Text] [Related]
37. Identification of Prognostic alternative splicing signatures and their clinical significance in uveal melanoma.
Zhou W; Fei P; Li J
Exp Eye Res; 2021 Aug; 209():108666. PubMed ID: 34129849
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
[TBL] [Abstract][Full Text] [Related]
39. Repression of genes involved in melanocyte differentiation in uveal melanoma.
Bergeron MA; Champagne S; Gaudreault M; Deschambeault A; Landreville S
Mol Vis; 2012; 18():1813-22. PubMed ID: 22815634
[TBL] [Abstract][Full Text] [Related]
40. Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma.
Zhan Z; Lin K; Wang T
BMC Ophthalmol; 2024 May; 24(1):204. PubMed ID: 38698303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
